Jun-Xu Li, MD, PhD, has been awarded a five-year, $2 million National Institutes of Health grant to investigate a novel therapy that may prove more powerful than currently available smoking cessation treatments.
The Jacobs School of Medicine and Biomedical Sciences and UB’s Clinical and Research Institute on Addictions (CRIA) played host to a prestigious Fulbright Enrichment Seminar on the opioid epidemic that brought 79 Fulbright Foreign Students from 51 countries to downtown Buffalo.
The PhD Program in Biomedical Sciences (PPBS) conducted its third annual white coat ceremony to recognize 19 students from the Class of 2018-2019 — 14 doctoral students and five MD-PhD students — who completed their first year in the program and are moving on to their research laboratory match.
Jun-Xu Li, MD, PhD, associate professor of pharmacology and toxicology, is being recognized by the American Society for Pharmacology and Experimental Therapeutics (ASPET) with the inaugural JH Woods Early Career Award in Behavioral Pharmacology.
New stem cell research led by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology, has identified novel therapeutic targets for the treatment of multiple sclerosis (MS) and other inflammatory diseases.
Nonprescription use of Ritalin may cause irreversible structural changes in certain areas of the brain, according to researchers in the Department of Pharmacology and Toxicology and UB’s Clinical and Research Institute on Addictions (CRIA).
Jennifer A. Martin, a doctoral student in the Department of Pharmacology and Toxicology, has received a prestigious Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience Award from the National Institutes of Health (NIH).